Day: May 2, 2023
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and